Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Gains from Investment Securities (2021 - 2022)

Northwest Biotherapeutics (NWBO) has 2 years of Gains from Investment Securities data on record, last reported at $304.6 million in Q3 2022.

  • For Q3 2022, Gains from Investment Securities changed N/A year-over-year to $304.6 million; the TTM value through Sep 2022 reached $304.6 million, changed N/A, while the annual FY2024 figure was $364000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached $304.6 million in Q3 2022 per NWBO's latest filing, roughly flat from $304.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $304.8 million in Q4 2021 and bottomed at $304.6 million in Q3 2022.